J Fuhlendorff
Overview
Explore the profile of J Fuhlendorff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
207
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ladriere L, Fuhlendorff J, Malaisse W
Endocrine
. 1998 Jul;
7(3):311-7.
PMID: 9657067
Several meglitinide analogs are currently under investigation as potential insulinotropic tools for the treatment of noninsulin-dependent diabetes. The present study aimed to further insight into the effect of these agents...
2.
Fuhlendorff J, Rorsman P, Kofod H, Brand C, Rolin B, MacKay P, et al.
Diabetes
. 1998 Mar;
47(3):345-51.
PMID: 9519738
The action of repaglinide, a novel insulin secretagogue, was compared with the sulfonylurea glibenclamide with regard to the hypoglycemic action in vivo, binding to betaTC-3 cells, insulin secretion from perifused...
3.
Ladriere L, Malaisse-Lagae F, Fuhlendorff J, Malaisse W
Eur J Pharmacol
. 1997 Nov;
335(2-3):227-34.
PMID: 9369378
Repaglinide (1 microg/g body wt), glibenclamide (10 microg/g) or glimepiride (10 microg/g) were administered orally to either fed or overnight fasted normal rats and hereditarily diabetic animals (GK rats). In...
4.
Ladriere L, Malaisse-Lagae F, Fuhlendorff J, Malaisse W
Res Commun Mol Pathol Pharmacol
. 1997 Jul;
97(1):53-9.
PMID: 9507568
The hypoglycemic agents, glibenclamide and repaglinide, when administered intragastrically to overnight fasted hereditarily diabetic animals, were found to oppose the rise in the plasma insulin/glucose ratio otherwise evoked by refeeding...
5.
Springborg J, Gromada J, Madsen P, Varming A, Fuhlendorff J
Adv Exp Med Biol
. 1997 Jan;
426:149-57.
PMID: 9544268
No abstract available.
6.
Sheikh S, Roach E, Fuhlendorff J, Williams J
Am J Physiol
. 1991 Feb;
260(2 Pt 1):G250-7.
PMID: 1847590
To localize binding sites for peptide YY (PYY) in the pancreas we utilized a slide-mount autoradiographic technique on frozen sections of rat pancreas incubated with 125I-Tyr36-PPY. Saturable autoradiographic labeling was...
7.
Potter E, Fuhlendorff J, Schwartz T
Eur J Pharmacol
. 1991 Jan;
193(1):15-9.
PMID: 2050189
Anaesthetised rats and dogs were used to study the pre- and postjunctional actions of neuropeptide Y (NPY) and [Pro34]NPY simultaneously. Increases in arterial blood pressure indicated postjunctional actions and both...
8.
Jorgensen J, Fuhlendorff J, Schwartz T
Eur J Pharmacol
. 1990 Sep;
186(1):105-14.
PMID: 2178092
The biological effects of neuropeptide Y (NPY), rat pancreatic polypeptide (rPP), hybrid analogs of NPY and PP, and C-terminal fragments of NPY were studied in the field-stimulated rat vas deferens...
9.
The antiparallel pancreatic polypeptide fold in the binding of neuropeptide Y to Y1 and Y2 receptors
Fuhlendorff J, Johansen N, Melberg S, Thogersen H, Schwartz T
J Biol Chem
. 1990 Jul;
265(20):11706-12.
PMID: 2164012
Neuropeptide Y (NPY) belongs to the pancreatic polypeptide fold (PP-fold) family of regulatory peptides. Analysis of circular dicroic spectra of NPY showed that it has a high degree of secondary...
10.
Aakerlund L, Gether U, Fuhlendorff J, Schwartz T, Thastrup O
FEBS Lett
. 1990 Jan;
260(1):73-8.
PMID: 2153577
Two types of binding sites have previously been described for neuropeptide Y (NPY), called Y1 and Y2 receptors. The intracellular events following Y1 receptor activation was studied in the human...